DR. JOSEPH ELIAS KHABBAZA M.D.
Prescription History 1760645428
Internal Medicine - Pulmonary Disease in Akron, OH

NPI Status: Active since July 02, 2008

Contact Information

224 W. EXCHANGE ST.
SUITE 380
AKRON, OH
ZIP 44302
Phone: (330) 344-6676
Fax: (330) 434-3611

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOSEPH ELIAS KHABBAZA M.D., an active Pulmonary Disease specialist practicing in Akron, OH. Our medical registry currently tracks 31 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,638 documented patient claims. Among these therapy options, the most frequently utilized medication is Azithromycin, which accounts for 190 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 510
OH State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply896
Conservative Utilization

This provider writes prescriptions for this formulation 47.6% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,072.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$642.93

State Avg Cost Per Claim

$560.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 42
30-Day Fills 50.0
Days Supply 1,500
OH State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply864
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 90.9% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,408.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$533.54

State Avg Cost Per Claim

$618.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 162
30-Day Fills 215.0
Days Supply 5,380
OH State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills79.6
Peer Average Days Supply1,966
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 149.2% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,420.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.80

State Avg Cost Per Claim

$49.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amitriptyline Hcl

Generic Formulation: Amitriptyline HclSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 11
30-Day Fills 19.0
Days Supply 570
OH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills49.1
Peer Average Days Supply1,449
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.52

State Avg Cost Per Claim

$21.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, help you sleep better, and increase your energy level. This medication belongs to a class of medications called tricyclic antidepressants. It works by affecting the balance of certain natural chemicals (neurotransmitters such as serotonin) in the brain.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 93
30-Day Fills 131.0
Days Supply 3,930
OH State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills40.8
Peer Average Days Supply1,203
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 190.6% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $64,778.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$696.54

State Avg Cost Per Claim

$583.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arikayce

Generic Formulation: Amikacin Liposomal/Neb.AccessrSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 700
OH State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.9
Peer Average Days Supply478
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 66.7% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $370,627.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,825.09

State Avg Cost Per Claim

$14,185.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to treat a certain lung infection (Mycobacterium avium complex-MAC) after other treatments have not worked. Amikacin belongs to a class of drugs known as aminoglycoside antibiotics. This medication works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
OH State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills30.7
Peer Average Days Supply919
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,020.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$232.34

State Avg Cost Per Claim

$297.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 190
30-Day Fills 255.9
Days Supply 7,180
OH State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills38.5
Peer Average Days Supply312
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 427.8% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,806.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.30

State Avg Cost Per Claim

$9.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Bevespi Aerosphere

Generic Formulation: Glycopyrrolate/Formoterol FumSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 56
30-Day Fills 63.0
Days Supply 1,890
OH State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply697
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 180.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,702.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$512.55

State Avg Cost Per Claim

$496.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 80
30-Day Fills 98.0
Days Supply 2,938
OH State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills43.3
Peer Average Days Supply1,282
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 142.4% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,159.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$514.49

State Avg Cost Per Claim

$517.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 82
30-Day Fills 102.0
Days Supply 3,060
OH State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills41.7
Peer Average Days Supply1,248
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 141.2% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $67,036.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$817.52

State Avg Cost Per Claim

$765.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
OH State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply619
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,966.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$228.17

State Avg Cost Per Claim

$356.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Ceftazidime

Generic Formulation: CeftazidimeSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.9
Days Supply 1,127
OH State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply189
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 115.8% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,577.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$87.25

State Avg Cost Per Claim

$81.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.

Therapeutic Applications

Ceftazidime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 349
OH State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.1
Peer Average Days Supply258
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $443.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.41

State Avg Cost Per Claim

$7.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 412
OH State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply438
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $463.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.53

State Avg Cost Per Claim

$25.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 29
30-Day Fills 49.0
Days Supply 1,470
OH State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply763
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.1% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,973.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$550.80

State Avg Cost Per Claim

$454.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Ethambutol Hcl

Generic Formulation: Ethambutol HclSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 57
30-Day Fills 75.5
Days Supply 2,242
OH State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply713
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 200.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,927.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.36

State Avg Cost Per Claim

$56.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)

Therapeutic Applications

Ethambutol is used with other medications to treat tuberculosis (TB). Ethambutol is an antibiotic and works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 17
30-Day Fills 34.0
Days Supply 1,020
OH State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply875
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,459.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$438.77

State Avg Cost Per Claim

$405.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 15
30-Day Fills 29.0
Days Supply 870
OH State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply824
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,573.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$438.24

State Avg Cost Per Claim

$223.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 18
30-Day Fills 48.0
Days Supply 1,440
OH State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills30.6
Peer Average Days Supply878
Conservative Utilization

This provider writes prescriptions for this formulation 28.0% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,584.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$976.92

State Avg Cost Per Claim

$433.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 50
30-Day Fills 116.0
Days Supply 3,480
OH State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills121.9
Peer Average Days Supply3,603
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $682.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.64

State Avg Cost Per Claim

$19.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 840
OH State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.6
Peer Average Days Supply944
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235,084.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,395.88

State Avg Cost Per Claim

$12,300.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
OH State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.5
Peer Average Days Supply670
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59,439.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,714.96

State Avg Cost Per Claim

$5,757.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 158
30-Day Fills 189.9
Days Supply 4,504
OH State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills61.0
Peer Average Days Supply1,076
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 209.8% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $982.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.22

State Avg Cost Per Claim

$5.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Rifampin

Generic Formulation: RifampinSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,076
OH State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply647
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,087.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.75

State Avg Cost Per Claim

$71.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 34
30-Day Fills 48.0
Days Supply 1,438
OH State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills45.3
Peer Average Days Supply1,358
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,531.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$750.92

State Avg Cost Per Claim

$677.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 51
30-Day Fills 69.0
Days Supply 2,070
OH State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,287
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 64.5% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,899.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$664.70

State Avg Cost Per Claim

$649.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 289
OH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply494
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $106.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.58

State Avg Cost Per Claim

$5.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 121
30-Day Fills 166.5
Days Supply 4,995
OH State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills50.1
Peer Average Days Supply1,503
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 245.7% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,714.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$501.77

State Avg Cost Per Claim

$540.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 97
30-Day Fills 118.0
Days Supply 3,540
OH State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills66.5
Peer Average Days Supply1,988
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 94.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $79,134.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$815.82

State Avg Cost Per Claim

$852.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 26
30-Day Fills 29.9
Days Supply 739
OH State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply744
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,017.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.59

State Avg Cost Per Claim

$73.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOSEPH ELIAS KHABBAZA M.D. provides transparency into local medical care patterns within Akron, OH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.